James Jett, MD, is an internationally known expert in lung-cancer therapy. He is co-chief medical officer of Biodesix, Inc in Boulder, Colorado. The company is involved in biomarker tests for advanced lung cancer and indeterminate pulmonary nodules.
He has been a leader in identifying the value of CT screening for early detection of lung cancer. Dr. Jett received his MD at the University of Missouri. He has held appointments as professor of medicine at Mayo Medical School and the University of Pittsburgh and has served as a consultant for the National Cancer Institute in Bethesda, Maryland. Dr. Jett is emeritus editor of the Journal of Thoracic Oncology. Previously he has served on the editorial board for other major medical journals, including Chest, Respiratory Medicine, and American Journal of Respiratory and Critical Care Medicine.
